Recerca

Àrea 5

Oncologia Molecular i Translacional

Factor d'impacte: mitjana: 7.08, total: 247.96

Articles de l'any 2010
Original
  • HER2 Silences Tumor Suppression in Breast Cancer Cells by Switching Expression of C/EBP beta Isoforms

    Arnal-Estape A, Tarragona M, Morales M, Guiu M, Nadal C, Massague J, Gomis RR
    CANCER RES. 2010; 70: 9927-9936. IF: 7.543

  • Pharmacodynamic Trial of Nimotuzumab in Unresectable Squamous Cell Carcinoma of the Head and Neck: A SENDO Foundation Study

    Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeno M, Campas C, Osorio M, Iznaga N, Bellosillo B, Rovira A, Marsoni S, Gascon P, Serrano S, Sessa C, Crombet T, Albanell J
    CLIN CANCER RES. 2010; 16: 2474-2482. IF: 6.747

  • Development of a new G-CSF product based on biosimilarity assessment

    Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, Einmahl S, Muenzberg M
    ANN ONCOL. 2010; 21: 1419-1429. IF: 5.647

  • Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

    Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, Lopez-Guerrero JA, Martinez-Trufero J, DeSande LM, Lainez N, Maurel J, DeJuan A, Losa F, Andres R, Casado A, Tejido PG, Blanco R, Carles J, Bellmunt J, Gomez-Espana A, Ramos R, Martinez-Serra J, Llombart-Bosch A, Poveda A
    ANN ONCOL. 2010; 21: 1552-1557. IF: 5.647

  • Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study

    Gascon P, Pirker R, DelMastro L, Durrwell L
    ANN ONCOL. 2010; 21: 2029-2039. IF: 5.647

  • Imatinib Plus Low-Dose Doxorubicin in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to High-Dose Imatinib A Phase I-II Study by the Spanish Group for Research on Sarcomas

    Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ayuso JR, Lopez-Pousa A, Garcia-Albeniz X, DelMuro XG, DeAlava E
    CANCER-AM CANCER SOC. 2010; 116: 3692-3701. IF: 5.418

  • Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.

    Martin M, Segui MA, Anton A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodriguez-Lescure A, Grosse R, Calvo L, Barnadas A, Isla D, DelPrado PM, Borrego M, Zaluski J, Arcusa A, Munoz M, Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florian J, Li JF, Garcia-Asenjo JA, Saez A, Rios M, Almenar S, Peiro G, Lluch A
    NEW ENGL J MED. 2010; 363: 2200-2210. IF: 47.05

  • Tumor promoting effects of CD95 signaling in chemoresistant cells

    Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Carbo N, Pastor-Arroyo EM, Gascon P, Almendro V
    MOL CANCER. 2010; 9: 0-0. IF: 4.16

  • Incidence of occult mediastinal node involvement in cNO non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan

    Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer JM, Marrades R, Lomena F
    EUR J CARDIO-THORAC. 2010; 37: 1168-1174. IF: 2.397

  • Phase II, Randomized Study of Concomitant Chemoradiotherapy Followed by Surgery and Adjuvant Capecitabine Plus Oxaliplatin (CAPOX) Compared With Induction CAPOX Followed by Concomitant Chemoradiotherapy and Surgery in Magnetic Resonance Imaging-Defined, L

    Fernandez-Martos C, Pericay C, Aparicio J, Salud A, Safont M, Massuti B, Vera R, Escudero P, Maurel J, Marcuello E, Mengual JL, Saigi E, Estevan R, Mira M, Polo S, Hernandez A, Gallen M, Arias F, Serra J, Alonso V
    J CLIN ONCOL. 2010; 28: 859-865. IF: 17.793

  • Large Randomized Study of Thymosin alpha 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma

    Maio M, Mackiewicz A, Testori A, Trefzer U, Ferraresi V, Jassem J, Garbe C, Lesimple T, Guillot B, Gascon P, Gilde K, Camerini R, Cognetti F
    J CLIN ONCOL. 2010; 28: 1780-1787. IF: 17.793

  • Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

    Molina R, Auge JM, Escudero JM, Filella X, Zanon G, Pahisa J, Farrus B, Munoz M, Velasco M
    TUMOR BIOL. 2010; 31: 171-180. IF: 1.94

  • Predicting Non-Sentinel Lymph Node Status in Breast Cancer Patients with Sentinel Lymph Node Involvement: Evaluation of Two Scoring Systems

    Sanjuan A, Escaramis G, Vidal-Sicart S, Illa M, Zanon G, Pahisa J, Rubi S, Velasco M, Santamaria G, Farrus B, Munoz M, Garcia Y, Fernandez PL, Pons F
    BREAST J. 2010; 16: 134-140. IF: 1.61

  • Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment

    Casas F, Borras JM, Ferrer F, Guanyabens N, Gutierrez R, Leon C, Lopez J, Mellado B, Morote J, Puig J, Ribal J, Serra A, Valls V, Zapatero A
    CLIN TRANSL ONCOL. 2010; 12: 346-355. IF: 1.146

  • Potential usefulness of an EPA-enriched nutritional supplement on chemotherapy tolerability in cancer patients without overt malnutrition

    Trabal J, Leyes P, Forga M, Maurel J
    NUTR HOSP. 2010; 25: 736-740. IF: 1.065

Revisió
  • Current perspectives of treatment of ductal carcinoma in situ

    Estevez LG, Alvarez I, Segui MA, Munoz M, Margeli M, Miro C, Rubio C, Lluch A, Tusquets I
    CANCER TREAT REV. 2010; 36: 507-517. IF: 5.295

  • Tyrosine Kinase Receptor Transactivation Associated to G Protein-Coupled Receptors

    Almendro V, Garcia-Recio S, Gascon P
    CURR DRUG TARGETS. 2010; 11: 1169-1180. IF: 3.932

  • Current controversies in the management of breast cancer

    Tusquets I, Garcia-Estevez L, Adrover E, Calvo L, Alvarez I, Mata JG, Fernandez Y, Margueli M, Segui MA, Rodriguez C, Lescure AR, Colomer R, Gascon P, Martin M, Alba E, Barnadas A, Llombart A, Albanell J, Lluch A
    CLIN TRANSL ONCOL. 2010; 12: 278-286. IF: 1.146

Editorials
  • Sentinel lymph node and neoadjuvant therapy in breast cancer

    Munoz M, Pahisa J, Caparros FX, Vidal-Sicart S
    REV ESP MED NUCL. 2010; 29: 319-320. IF: 0.765

Multicèntrics
  • Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis

    Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, VanCutsem E, Buyse M
    JAMA-J AM MED ASSOC. 2010; 303: 1729-1737. IF: 28.899

  • The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up

    Steinberg MH, Mccarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, Decastro L, Waclawiw MA
    AM J HEMATOL. 2010; 85: 403-408. IF: 2.61

  • Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

    Beyer J
    J CLIN ONCOL. 2010; 28: 4906-4911. IF: 17.793

Guies clíniques
  • Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part I). Grupo Español de Consenso en Cáncer de Páncreas.

    Navarro S, Vaquero E, Maurel J, Bombi JA, DeJuan C, Feliu J, Cruz LF, Gines A, Girela E, Rodriguez R, Sabater L
    MED CLIN-BARCELONA . 2010; 134: 643-655. IF: 1.231

  • Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part II)

    Navarro S, Vaquero E, Maurel J, Bombi JA, DeJuan C, Feliu J, Cruz LF, Gines A, Girela E, Rodriguez R, Sabater L
    MED CLIN-BARCELONA. 2010; 134: 692-702. IF: 1.231

Tornar